ADVERTISEMENT
ADVERTISEMENT

The Bubble Bursts

Data derived from the Science Watch/Hot Papers database and the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average paper of the same type and age. M. Cavazzana-Calvo et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," Science, 288:669-72, April 28, 2000. (Cited in 300 papers) Reaching positive milestones in gene therapy has been difficult since a highly publicized death in 1999,1 but some have succeede

Brendan Maher
Data derived from the Science Watch/Hot Papers database and the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average paper of the same type and age.

M. Cavazzana-Calvo et al., "Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease," Science, 288:669-72, April 28, 2000. (Cited in 300 papers)

Reaching positive milestones in gene therapy has been difficult since a highly publicized death in 1999,1 but some have succeeded. A major break came this year when researchers in Italy and Israel reported successfully treating two patients with ADA-SCID, a form of severe combined immunodeficiency that results from a defective gene for adenosine deaminase (ADA).2 In 2000--in the wake of gene therapy's darkest hour--a French group reported similar results for X-linked SCID, a form of the disease caused by a mutation in the common cytokine receptor gamma chain...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT